• Special Issue Topic

    Theranostic Frontiers in Neuro-Oncology

    Submission Deadline: August 31, 2022

    Guest Editor

    Prof. Chunsheng Kang E-Mail

    Deputy Director of Tianjin Neurology Institute, Director of Neuro-tumor Laboratory of Tianjin Medical University General Hospital, Tianjin, China

    Research Keywords: Nano-medicine; signaling pathways; exosome and endocytosis; gene editing; neuro-oncology


    About the Special Issue

    Among the tumors of the central nervous system, glioblastoma is currently the most challenging tumor for neurosurgeons. Benign tumors are also challenging diseases for surgical procedures because of deep location with brain. In recent years, with the development of genomics, proteomics and metabolomics, the understanding of neuro-oncology has been deepened, and new diagnostic markers, diagnostic techniques and treatment strategies have been developed in both clinical diagnosis and therapeutics. The special issue will focus on the application of new methods, viewpoints and technologies for the diagnosis and treatment of brain tumors including brain metastases. Novel research methods including immune markers and single-cell sequencing are also welcome. The topic will cover the scope of imaging, pathology, neurosurgery, neuro-oncology and basic research. Reviews, comments and research article within the scope are welcomed for submission.

    Keywords: Neuro-oncology; brain metastasis; imaging; surgical technology; pathology; biomarker; single cell sequencing; immunology

    Call for Papers

    Published Articles

    Open Access
    Review
    Research progress in molecular pathology markers in medulloblastoma
    Glioblastoma is the most common and malignant primary brain tumor. Despite a century of research efforts, the survival of patients has not significantly improved. Currently, diagnosis is based on ne [...] Read more.
    Zixuan Zhou ... Shangfeng Gao
    Published: February 28, 2023 Explor Target Antitumor Ther. 2023;4:139–156
    DOI: https://doi.org/10.37349/etat.2023.00126
    View:1128
    Download:26
    Open Access
    Review
    Liquid biopsy and glioblastoma
    Glioblastoma is the most common and malignant primary brain tumor. Despite a century of research efforts, the survival of patients has not significantly improved. Currently, diagnosis is based on ne [...] Read more.
    Robert H. Eibl, Markus Schneemann
    Published: February 25, 2023 Explor Target Antitumor Ther. 2023;4:28–41
    DOI: https://doi.org/10.37349/etat.2023.00121
    View:1996
    Download:39
    Open Access
    Perspective
    Encouraging probiotics for the prevention and treatment of immune-related adverse events in novel immunotherapies against malignant glioma
    Among the malignant tumors in the central nervous system (CNS), glioma is the most challenging tumor to the public society, which accounts for the majority of intracranial malignant tumors with impa [...] Read more.
    Sayuri Yoshikawa ... Satoru Matsuda
    Published: December 27, 2022 Explor Target Antitumor Ther. 2022;3:817–827
    DOI: https://doi.org/10.37349/etat.2022.00114
    View:3225
    Download:1404
    Open Access
    Review
    Perspectives of traditional Chinese medicine to patch up immune checkpoint blockers
    In this era of cancer immunotherapy, the response rates of immune checkpoint blockers (ICBs) are still too low and the adverse events may also be significant. Of the ways of patching up such deficit [...] Read more.
    Shiu Ying Tsao
    Published: October 31, 2022 Explor Target Antitumor Ther. 2022;3:676–693
    DOI: https://doi.org/10.37349/etat.2022.00107
    View:1466
    Download:22
    Open Access
    Original Article
    N6-methyladenosine-related microRNAs risk model trumps the isocitrate dehydrogenase mutation status as a predictive biomarker for the prognosis and immunotherapy in lower grade gliomas
    Aim: Lower grade gliomas [LGGs; World Health Organization (WHO) grades 2 and 3], owing to the heterogeneity of their clinical behavior, present a therapeutic challenge to  [...] Read more.
    Feng Yuan ... Chiyuan Ma
    Published: September 30, 2022 Explor Target Antitumor Ther. 2022;3:553–569
    DOI: https://doi.org/10.37349/etat.2022.00100
    View:1483
    Download:40